Cancer treatments

GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates

Retrieved on: 
Monday, September 6, 2021

(hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.

Key Points: 
  • (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007.
  • In recent years, immunotherapeutic antibody drugs targeting PD-1 and PD-L1 (representing immune checkpoint inhibitors) have revolutionized cancer therapy.
  • Linker stability is extremely important in the field of antibody immune agonist conjugates.
  • GeneQuntum focuses on the development of differentiated innovation products through in-house research and development and diversified external research and development cooperation.

F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA

Retrieved on: 
Wednesday, August 4, 2021

Under the terms of the agreement, MSD will supply KEYTRUDA for a combination arm that will be included in theadaptive Phase 1 clinical protocol of FS120, sponsored by F-star,thatwas initiatedin December of 2020.

Key Points: 
  • Under the terms of the agreement, MSD will supply KEYTRUDA for a combination arm that will be included in theadaptive Phase 1 clinical protocol of FS120, sponsored by F-star,thatwas initiatedin December of 2020.
  • FS120 is currently being exploredas a monotherapy in dose escalation (NCT04648202) , including the evaluation of pharmacokinetics and pharmacodynamics in patients with advanced cancer.
  • FS120 will also be evaluated in combination withKEYTRUDA,with the potential for early demonstration of clinical activity in specifictumorsubtypes.
  • In preclinical studies, FS120 has demonstrated strong additive effects in combination with PD-1 monoclonal antibodies.

 UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, August 4, 2021

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005328/en/

iOnctura Boosts Management Team With Appointment of David Seeberger as VP Finance

Retrieved on: 
Wednesday, August 4, 2021

iOnctura SA is a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface.

Key Points: 
  • iOnctura SA is a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface.
  • iOncturas best-in-class drug development programs combine immune-mediated and direct anti-tumor activity to deliver molecules with superior clinical efficacy and safety in oncology.
  • iOncturas second program, IOA-289, is an oral small molecule that inhibits the cross-talk between the tumor and its stroma and is in a Phase 1 clinical study.
  • iOnctura is backed by blue chip investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund.

Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer

Retrieved on: 
Monday, August 2, 2021

The collaboration will utilize Roches MORPHEUS Phase 1b/2 platform for rapid and efficient combination development, with upfront randomization versus a control group.

Key Points: 
  • The collaboration will utilize Roches MORPHEUS Phase 1b/2 platform for rapid and efficient combination development, with upfront randomization versus a control group.
  • This new study expands Carricks portfolio of clinical trials with samuraciclib, which is also being evaluated in a Phase 2a study in combination with fulvestrant for CDK4/6i resistant HR+, HER2- metastatic breast cancer.
  • We are excited to initiate this collaboration with Roche to explore the broad potential of samuraciclib in combination with giredestrant, a next-generation oral SERD, said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • Samuraciclib is also being evaluated in triple negative breast cancer (TNBC) and prostate cancer with further potential in pancreatic, ovarian and colorectal cancers.

Atreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid Tumors

Retrieved on: 
Thursday, July 29, 2021

SAN CARLOS, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced initial data from the dose escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types that displayed greater than 50% target expression in preclinical studies.

Key Points: 
  • "We are pleased to present initial summary data from our first-in-human study of ATRC-101, said Jonathan Benjamin, M.D., Ph.D., Sr. Vice President, Clinical Research.
  • The Phase 1b trial is a first-in-human, open-label study of ATRC-101 in patients with select solid tumor cancers, utilizing a 3+3 design for the dose escalation portion.
  • Atreca expects to report additional monotherapy data by mid-2022, pembrolizumab combination data in mid-2022 and chemotherapy combination data in late 2022.
  • Atreca initiated a Phase 1b first-in-human study of ATRC-101 in participants with select solid tumor cancers in early 2020.

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy

Retrieved on: 
Friday, July 30, 2021

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).
  • Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.
  • By harnessing the bodys own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
  • OPDIVO (nivolumab), in combination with cabozantinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction

Retrieved on: 
Thursday, July 29, 2021

SUZHOU, China, July 28, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to TST001, its anti-Claudin18.2 monoclonal antibody currently in Phase I clinical trial, for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ).

Key Points: 
  • SUZHOU, China, July 28, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to TST001, its anti-Claudin18.2 monoclonal antibody currently in Phase I clinical trial, for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ).
  • According to preclinical and clinical data, TST001 displayed potent anti-tumor activities in tumor model of gastric cancer or patient of gastric cancer expressing Claudin18.2.
  • At present, the treatment options of gastric cancer expressing Claudin18.2 are very limited other than surgical resection, chemotherapy and most recently immunotherapy.
  • Orphan Drug Designation (ODD) is granted by the FDA to drugs intended to treat rare disorders that affect fewer than 200,000 people in the U.S.

Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results

Retrieved on: 
Wednesday, July 28, 2021

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.

Key Points: 
  • NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.
  • To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
  • The call will also be available over the Internet and accessible at:
    Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • The companys proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021

Retrieved on: 
Wednesday, July 28, 2021

A live webcast of the presentation will be available under Events and Presentations in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .

Key Points: 
  • A live webcast of the presentation will be available under Events and Presentations in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs).
  • The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.